Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer
Florian Malchers, … , Julie George, Roman K. Thomas
Florian Malchers, … , Julie George, Roman K. Thomas
Published August 22, 2023
Citation Information: J Clin Invest. 2023;133(21):e170217. https://doi.org/10.1172/JCI170217.
View: Text | PDF
Research Article Genetics Oncology

Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer

  • Text
  • PDF
Abstract

The discovery of frequent 8p11-p12 amplifications in squamous cell lung cancer (SQLC) has fueled hopes that FGFR1, located inside this amplicon, might be a therapeutic target. In a clinical trial, only 11% of patients with 8p11 amplification (detected by FISH) responded to FGFR kinase inhibitor treatment. To understand the mechanism of FGFR1 dependency, we performed deep genomic characterization of 52 SQLCs with 8p11-p12 amplification, including 10 tumors obtained from patients who had been treated with FGFR inhibitors. We discovered somatically altered variants of FGFR1 with deletion of exons 1–8 that resulted from intragenic tail-to-tail rearrangements. These ectodomain-deficient FGFR1 variants (ΔEC-FGFR1) were expressed in the affected tumors and were tumorigenic in both in vitro and in vivo models of lung cancer. Mechanistically, breakage-fusion-bridges were the source of 8p11-p12 amplification, resulting from frequent head-to-head and tail-to-tail rearrangements. Generally, tail-to-tail rearrangements within or in close proximity upstream of FGFR1 were associated with FGFR1 dependency. Thus, the genomic events shaping the architecture of the 8p11-p12 amplicon provide a mechanistic explanation for the emergence of FGFR1-driven SQLC. Specifically, we believe that FGFR1 ectodomain–deficient and FGFR1-centered amplifications caused by tail-to-tail rearrangements are a novel somatic genomic event that might be predictive of therapeutically relevant FGFR1 dependency.

Authors

Florian Malchers, Lucia Nogova, Martijn H.A. van Attekum, Lukas Maas, Johannes Brägelmann, Christoph Bartenhagen, Luc Girard, Graziella Bosco, Ilona Dahmen, Sebastian Michels, Clare E. Weeden, Andreas H. Scheel, Lydia Meder, Kristina Golfmann, Philipp Schuldt, Janna Siemanowski, Jan Rehker, Sabine Merkelbach-Bruse, Roopika Menon, Oliver Gautschi, Johannes M. Heuckmann, Elisabeth Brambilla, Marie-Liesse Asselin-Labat, Thorsten Persigehl, John D. Minna, Henning Walczak, Roland T. Ullrich, Matthias Fischer, Hans Christian Reinhardt, Jürgen Wolf, Reinhard Büttner, Martin Peifer, Julie George, Roman K. Thomas

×

Figure 3

Oncogenic potential of an ectodomain-deficient version of FGFR1.

Options: View larger image (or click on image) Download as PowerPoint
Oncogenic potential of an ectodomain-deficient version of FGFR1.
(A) Ove...
(A) Overview of FGFR1 protein variants using the next possible in-frame ATG start codon of the transcripts shown in Figure 1I and Figure 2G. AB, acid box; TM, transmembrane domain. (B) Immunoblots of Ba/F3 cells transduced with retroviruses encoding ΔEC-FGFR1 and EML4-ALK (control), as well as parental Baf3 cells or cells transduced with empty vector (Baf3 e.v.), FGFR1α (Baf3 FGFR1alpha), FGFR1β, and (Baf3 FGFR1beta). Baf3 e.v, FGFR1α, and FGFR1β were cultured with IL-3. t, total. (C) Baf3 e.v., FGFR1β, and ectodomain lacking FGFR1 (ΔEC-FGFR1, using an in-frame ATG in exon 9) were incubated with increasing concentrations of the FGFR inhibitor BGJ398 (BGJ, top) or the FGFR inhibitor AZD4547 (bottom) for 96 hours, with measurement of ATP content to determined viability. Baf3 e.v. and Baf3 FGFR1β cells were screened in the presence of IL-3, whereas Baf3 ΔEC-FGFR1 cells were screened without IL-3. (D) Quantification of xenograft tumor models engrafted with Ba/F3 cells expressing ΔEC-FGFR1 (blue) or EML4-ALK (red) following treatment with BGJ398 (20 mg/kg, q.d., red/blue bars) or vehicle (dashed red/blue bars). (E) Tumor volumes of a xenograft tumor model engrafted with Ba/F3 cells expressing ΔEC-FGFR1 that were treated with BGJ398 (20 mg/kg, q.d., blue curve) or vehicle (black curve), respectively, upon formation of palpable tumors. Tumor volumes were assessed as indicated and compared by 2-tailed t test. ***P < 0.0005. (F) Representative photographs of the xenograft models are shown before termination of the experiment.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts